Ionis Pharmaceuticals
IONS
301 hedge funds and large institutions have $5.84B invested in Ionis Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 103 increasing their positions, 89 reducing their positions, and 36 closing their positions.
28% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 36
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 89
2.47% more ownership
Funds ownership: 90.11% → 92.58% (+2.5%)
2% more funds holding
Funds holding: 294 → 301 (+7)
3% more capital invested
Capital invested by funds: $5.68B → $5.84B (+$155M)
17% less call options, than puts
Call options by funds: $71.6M | Put options by funds: $86.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$47.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$27.6M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$26.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$31.3M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$25.2M |
| 3 |
ClearBridge Investments
New York
|
-$20.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$10.2M |
| 5 |
AG
Artal Group
Luxembourg
|
-$6.87M |
IONS Hedge Fund Activity: Q3 2017 in Review
301 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2017, worth a combined $5.84B — up 2.7% from $5.68B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IONS positions and 36 closed out — a net gain of 10 holders — while 103 added to existing stakes and 89 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $47.9M. The largest seller was Waddell & Reed Financial, cutting an estimated $31.3M.
- 301 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2017, up from 294 in Q2 2017.
- Funds reported $5.84B of Ionis Pharmaceuticals stock for Q3 2017, up 2.7% quarter-over-quarter.
- 46 funds opened new Ionis Pharmaceuticals positions in Q3 2017 and 36 closed out, a net change of +10 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2017 was Wellington Management Group, an estimated $47.9M added.
- The largest Ionis Pharmaceuticals seller in Q3 2017 was Waddell & Reed Financial, an estimated $31.3M sold.
Based on aggregated 13F filings for Q3 2017.